Content area

|
|

SGLT2-inhibitorassocieret euglykæmisk diabetisk ketoacidose

Forfatter(e)
Frederikke Fisker1, 2, Niels Møller1 & Esben Stistrup Lauritzen1, 2
1) Medicinsk Forskningslaboratorium, Diabetes og Hormonsygdomme, Aarhus Universitetshospital 2) Steno Diabetes Center Aarhus, Aarhus Universitetshospital

Ugeskr Læger 2019;181:V02190125

Reference: 
Ugeskr Læger 2019;181:V02190125

Frederikke Fisker, Niels Møller & Esben Stistrup Lauritzen:

Sodium-glucose-cotransporter 2 inhibitor-associated euglycaemic diabetic ketoacidosis

Ugeskr Læger 2019;181:V02190125

This case report describes a 51-year-old man, who had Type 2 diabetes and was being treated with a sodium-glucose-cotransporter 2 inhibitor (SGLT2i). The patient developed euglycaemic diabetic ketoacidosis (DKA) during surgery.
A perioperative arterial blood gas analysis revealed metabolic acidosis (pH = 7.07), but the euglycaemic component of the DKA resulted in a delayed diagnosis of the DKA by 12 hours. A delayed diagnosis of DKA can be fatal, thus emphasising the importance of considering DKA as a diferential diagnosis in SGLT2i-treated patients with unspecific symptoms.

Du skal være logget ind for at læse denne artikel
Log ind

Right side